As AI systems increasingly generate novel drug candidates, patent law has yet to catch up. U.S. courts have ruled that only humans, not AI, can be named as inventors, requiring companies like Insilico Medicine to credit human researchers on patents even after publicly highlighting an AI platform’s role in “discovering” a drug. The gap raises questions about how significant a human contribution must be to qualify as invention and whether current patent policies can hold as AI takes on a larger role in drug development. Read more here.